The competitive binding of human a r antitrypsin and human a 2 -macroglobulin to porcine pancreatic elastase was studied. Mixtures of these two protease inhibitors, when titrated against elastase give Inhibition curves analogous to those obtained with human plasma. This is however not the case when the individual inhibitors are used. A theoretical treatment enabled us to devise an assay method to determine the amounts of functional activity of a r protease inhibitor and a 2 -macroglobulin respectively in human plasma.
Introduction
Since the first observations of antiproteolytic activity in blood in 1897 (1) at least nine protease inhibitors have been identified. The two major inhibitors are ctiaütitrypsin (now usually called c^-protease inhibitor) and a 2 -macrpglobulin, which represent about 70% of the plasma protease inhibitor activity by weight, and probably all the antirelastase activity (2) . Although both a r protease inhibitor and c^macroglobulin react with elastase, they do so in different ways. The former completely inhibits human neutrophil elastase using elastin äs Substrate, whereas a 2 -macroglobulin only partly inhibits this System (3).
The relationship between j-protease inhibitor defl· ciency and early onset of emphysema in individuals with genetic deficiency^ äs well äs in smokers is well documented (4, 5) . The di-protease inhibitor inhibits both the proteolytic and the amidolytic activity (on synthetic Substrates) of plasma proteases by binding to them and blocking their active sites (6) . The comp lex formed is very stable and does not dissociate even in the presence of other binders such äs <x 2 -macroglobulia (7).
The a 2 -macroglobulin present in human plasma binds to all four classes of endopeptidases (8) . On binding, the a 2 -macroglobulin molecule undergoes a conformational change which entraps the enzyme. In this way Inhibition does not involve interaction with the active site of the protease, and the bound enzyme still possesses activity toward low molecular weight Substrates (9) but decreased activity toward native proteins (10) . Consequently, when low molecular weight synthetic Substrates are used for measuring the protease inhibitory capacity of plasma, the protease bound to a r protease inhibitor will be completely inhibited. Ön the other hand, reaction with <x 2 -macroglobülin may cause only slight Inhibition of protease, or increased activity may even be found. When neutrophil elastase becomes complexed with a 2 -macroglobulin, its activity increases 15 to 16 times compared with that of the free enzyme (9) .
It has thus become clear that variable concentrations of a 2 -macroglobülin in plasma may modulate significantly the inhibitory role of aj-protease inhibitor in human plasma. In vivo, a balance is necessary in the synthesis and breakdown of elastin. It is possible that this homeostasis can be disturbed either by inactivatiön of cti-protease inhibitor by such factors äs smoking (11), or by changes in the activity of <x 2 -macroglobulin. In the latter case it is important to determine the level of a 2 -macroglobulin that can aotively bind protease, rather than the immunologically determined level. Several colorimetric methods have been developed to measure a 2 -macroglobulin in human blood, based on the ability of a 2 -macroglobulin protease complex to hydrolyse a low molecular weight synthetic Substrate in the presence of excess protease inhibitor.
Ganrot (12) used trypsin s the protease, benzoyl D,Larginine-p-nitroanilide s the Substrate and soybean trypsin inhibitor to block excess trypsin. More recently Cullmann & Dick (13) described a similar method using carbobenzoxy-Val-Gly-Arg-/?-nitroanilide s Substrate and aprotinin s the inhibitor; and Rao et al. (14) used a crude preparation of redwood seed extract (Adenanthera pavonia) s the source of inhibitor. None of these methods takes into account the endogenous serum a r protease inhibitor in the final calculation of the amount of a 2 -macroglobulin.
In this report, .we describe the competitive binding of a r protease inhibitor and a 2 -macroglobulin to porcine pancreatic elastase. The results are used to generate a method for assaying the amounts of functional activity of the two binders in human plasma.
Materials and Methods
Human a 2 -macroglobulin (90% pure), human α,-protease inhibitor and succinyltrialanyl-p-nitroanilide were obtained from Hoechst. Porcine pancreatic elastase (EC 3.4.21.11) was obtained from Boehringer, Mannheim.
Based on the manufacturer's specifications of 70 U/mg and the rate constant of 73 s~! quoted by Beith et al. (15) , this elastase is 40% pure.
Fresh human blood (10 ml) was drawn from a non-smoking volunteer into a lithium heparin Venoject tube. The buffer used for all assays was 0.1 mol/1 Tris-HCl pH 7.4. All chemicais used were of analytical grade (Merck).
Assumed molecular masses were: Porcine pancreatic elastase: M r = 25 000; α,-protease inhibitor: Af r = 54000; a 2 -macroglobulin: M T = 725000.
Theoretical model
Consider three simultaneous reactions (α,ΡΙ inhibitor, and a 2 -M = a 2 -macroglobulin): When a -h 2b > c
Here the competition between the two binders depends on the rate constants k, and k 2 , aecording to the following equation.
where Xo is the mol fraction of a r macroglobulin unbound (16, 17) . However, the bound fraction of the a 2 -macroglobulin will be distributed between binary and ternary complex, and.the amounts of each will depend on the amount of enzyme left at any particular time (16), taking into account the amount of ap rotease inhibitor and the rate of its binding to enzyme. Hence there is no simple relationship. However, since k 2 is greater than k, (17, 18) , the relative amount of enzyme bound to a 2 -macroglobulin will increase s the total amount pf added mixture of the 2 binders is increased. Hence we expect to find an increase in enzyme catalytic activity s the volume, V, increases beyond the equivalence point, V e . This accounts for the increase in catalytic activity after reaching a minimum in figure 1 . However, even if the volume added is increased to extremes, the maximum value attainable for the catalytic activity of the complexes is f 2 D 0 . D 0 = Absorbance produced by the elastase with no plasma added. f 2 = factor by which the catalytic activity of elastase is changed when it becomes complexed with a 2 -macroglobulin in the presence f excess a,-protease inhibitor.
When a + 2b < c
Since we allow sufficient time for the reaction to proceed to completion, all a and b are bound to enzyme. Also, all the a 2 -macroglobulin binds 2 elastase molecules per molecule a r macroglobulin (16) .
Hence, unreacted enzyme = c -a -2b
The observed catalytic activity for a volume, V, f mix-
where f, is the factor by which complexing of the enzyme with a 2 -macroglobulm decreases (or increases) its catalytic activity.
When plasma is titrated against porcine pancreatic elastase, the amounts of α,-protease inhibitor and a 2 -macroglobulin are in a constant ratio to each other in the plasma. elastase with a 2 -macroglobulin and then adding an excess of at-protease inhibitor after binding to a 2 -macroglobulin is complete.
Methods
Assay ofinhibitory capacity ofplasma towards porcine pancrea c elastase (flg. 1)
To (3 -x) ml of 0.1 mol/1 Tris-HCl buffer, 0.2 ml diluted elastase Suspension (270 pmol) was added. Various amounts of plasma (x ml) were added and incubated for 10 min at 37 °C. Fifty μΐ of succinyl-trialanyl-/?-nitroanilide (40 g/l) were then added and incubated for 20 min at 37 °C. The reaction was stopped with 0.5 ml 100 g/l citric acid. Absorbance was read at 410nm.
Titration of arprotease inhibitor against elastase (flg. 1)
Various volumes of a r protease inhibitor (8.9 mol/1) in buffer were added to 0.2 ml of diluted elastase Suspension (267 pmol per assay), and buffer added to a final volume of 3.2 ml. The residual elastase activity was measured s described above for plasma.
Titration of a r macroglobulin against elastase ( fig. 1) Various volumes of an a 2 -macroglobulin solution (417 nmol/1) were reacted for 5min at 37 °C with 1.6 nmol of porcine pancreatic elastase in Tris-bufYer of pH 7.4. The unreacted elastase was then neutralized with a large excess a r protease inhibitor (10 nmol) by reaction for a further 5 minutes at 37 °C. The volume of reaction mixture at this stage was 3.2 ml. Then 50 μΐ of succinyl-trialanyl-/j-nitroanilide (40 g/l) was added and incubated for 20 min at 37 °C. The reaction was stopped with 0.5 ml of citric acid solution (100 g/l). Absorbance was read at 410nm.
Titration ofmixtures of arprotease inhibitor and oLilin against elastase (fig. 2)
The concentrations of a r protease inhibitor and a 2 -macroglobulia in the mixtures are shown in the legend t figure 2. The assay was perfprmed s above, using 267 pmol of porcine pancreatic elastase.
Titration of elastase against a mixture ofboth inhibitor s (excess a r protease inhibitor added before measuring elastase activity)
. 3) A fixed amount of elastase (267 pmol per assay) was added to varying amounts of a mixture containing 7.5 μπιοΐ/ΐ of a 2 -macroglobulin and 2.34 umol/1 of arprotease inhibitor (0 to 100 μ!) in a total volume of 3.2 ml Tris^buffer at pH 7.4. After 5 min reaction at 37 °C the unbound elast se was neutralized by adding 10 ul of α! -pro tease Inhibitor (57 μοιρί/ϊ). Then 5 min later 50 μΐ of enzyme Substrate (40 g/l) was added and allowed to react for 20 min at 37 °C. The enzyme reaction was stopped with 0.5 ml of citric acid (100 g/l) and absorbance read at 410nm.
Determination off\
The value of f\ can be determined by measuring the catalytic activity of a known amount of enzyme alone and after adding an excess of a 2 -macroglobulin. The binary and ternary complexes have been shown to be equivalent, i. e. the two binding sites on a 2 -macroglobulin are identical (19) . Hence the question of which complex is formed when measuring fj is irrelevant.
Results and Discussion
As shown in table l the values obtained for fi and f 2 were: f, = 0.74 and f 2 = 0.70 at pH 7.4 These values are strongly dependent on the pH. How-•ever, since the pH Optimum for the complex between a 2 -macroglobulin and porcine pancreatic elastase is 7.4, all the assays were performed at this pH. Great care must be taken to adjust the pH exactly in order to obtain the above values for fi and f 2 . When normal human plasma was titrated against fixed amounts of elastase, a complex curve was obtained ( fig. 1 ), which has been ascribed by Meyer et al. (7) to the two main competing inhibitors in plasma, viz: a r protease inhibitor and <x 2 -macroglobulin.
The complex of a 2 -macroglobulin with porcine pancreatic elastase at pH 7.4 is at least 70% s catalytically active s the unbound elastase (tab. 1). The individual effects of each of these inhibitors on elastase, are shown in figure 1 . For aj-protease inhibitor the residual catalytic activity of the elastase was measured after the binding reaction was complete. A linear regression with negative slope was obtained. This was similar to the first half of the curve for plasma and indicated that arprotease inhibitor is probably the main factor responsible for the Inhibition observed in plasma. For the titration of a 2 -macroglobulin, we first allowed the binding of elastase to proceed to completion, then neutralized the excess elastase with fy-protease inhibitor, before adding Substrate (see methods section). The catalytic activity therefore represents that of the complex between a 2 -macroglobulin and porcine pancreatic elastase in the presence of excess protease inhibitor. This catalytic activity is only 70% of the catalytic activity of the free enzyme (tab. 1).
Here we obtained a straight line with positive slope ( fig. 1 ). This confirms that a 2 -macroglobulin is probably responsible for the second part of the curve for plasma (7), since this is the only known binder which protects porcine pancreatic elastase from Inhibition by a r protease inhibitor.
To investigate the phenomenon further we titrated various mixtures of a r protease inhibitor and a 2 -macroglobulin against fixed amounts of elastase. The results are shown in figure 2 . Using a constant amount of elastase (267 pmol) with the various mixtures, the amount of residual catalytic activity was related to the ratio of a t -protease inhibitor to a 2 -macroglobulin, s well s to the absolute amounts of each. As the relative amount of a r protease inhibitor was decreased, the equivalence volume (Ve) increased from 4 μΐ to 44 μΐ, with a concurrent ten fold increase in the absorbance at Ve. The curve depicted in figure l for plasma is similar in shape to those of figure 2 , where the second half of the curve is not exactly linear and becomes less linear s the amount of a.r protease inhibitor is reduced. This is beca se the Inhibition by cti-protease inhibitor is lower and a 2 -macroglobulin becomes more prominent. Hence the competition between the two is more obvious. This is added to the constraint that f 2 is smaller than f l5 and the value of the factor varies s the amount of di-protease inhibitor increases (see below). Furthermore, the maximum catalytic activity of the complex in the presence of excess a r protease inhibitor cannot exceed 0.7 times the catalytic activity of the uiicomplexed enzyme.
Although pure samples of arprotease inhibitor and <x 2 -macroglobulin gave linear regressions when titrated separately, detennination of a 2 -macroglobulin in a mixture of a r protease inhibitor and a 2 -macroglobulin produced a non-linear curve ( fig. 3) . Hence in devising a inethod for determining a 2 -macroglobulin in a mixture containing both inhibitors, this nonlinearity must be taken into account. In the suggested assay we use 10 μ! of plasma. This corresponds to the initial practically linear portion of the curve.
As a result of the above experiments certain modificar tions were made of the methods described above, in order to determine a 2 -macrogl bulin and arprotease inhibitor functional activities in plasma. of citric acid solution (100 g/l). D 0 is the absorbance at 410 nm developed in two minutes under these conditions. A blank is determined by adding the citric acid solution before the addition of Substrate.
Determination of a2-macroglobulin functional activity in plasma
In order to avoid the necessity of diluting the plasma we suggest an increased amount of porcine pancreatic elastase be used in contrast to that used in figure 1 . For most normal plasma 1.6 nmol per assay is satisfactorjf, giving an equivalence volume of about 40 μΐ of plasma in 3.2 ml of Tris-HCl buffer (0.1 mol/1) pH 7.4 at 37 °C for 10 min. The excess elastase is then reacted with an excess of <x r protease inhibitor (4 nmol) for a further 15 min at 37 °C. The residual catalytic activity, D 10 , for the 10 μΐ serum is determined by using succinyl-trialanyl-p-nitroanilide (2000 μg per assay), and incubating for 15 min (t 3 ) at 37 °C.
Determination of. functional activity of arprotease inhibitor in plasma
Except for patients in an acute phase, where the ajprotease inhibitor could rise to very high levels, we have found that satisfactory results are obtained with 20 μΐ of plasma and 1.6 nmol of porcine pancreatic elastase (100 μg of the 40% pure product) in 2.3 ml of Tris-buffer (0.1 mol/1 at pH 7.4). The two reactants are kept at 37 °C for 5 min. Then 50 μΐ of a solution of enzyme Substrate (40 g/J) is added and colour generation allowed to proceed for a further 5 min. The enzyme reaction is stopped by adding 0.5 ml of citric acid solution (100 g/l). Absorbance is read at 410 nm. A zero time blank is determined by adding the citric acid before adding the Substrate in a duplicate assay. 
Determination of equivalence point
The volume of plasma used for the above assay must not exceed V e . Hence it is useful to know this value.
At the equivalence point c = a + 2b = V c (A + 2B) V e = c/(A + 2B)
Hence we can calculate the Total Elastase Inhibiting Capacity (TEIC) which is defined s the number of ml of plasma required to bind l μπιοί of porcine pancreatic elastase. TEIC = V c χ 0.625 ml in our assay.
: As pointed out by Meyer et al. (7) the enzymatic 'determination of a r protease inhibitor is more specific : and much more rapid than immunological proce-'dures. The ability to determine the functional activities of both a r protease inhibitor and a 2 -macroglobuilin in the same specimen could be of importanee in the study of degenerative lung diseases.
A study of patients suffering from emphyserna has ishown that functional actiyity leVels of a2-macroglbulin in these patients are significaritly higher than .those in healthy persons. This data r will be published elsewhere.
